8.4 USP <800> Hazardous Drug Identification and Handling Precautions
Key Takeaways
- USP <800> sets comprehensive standards for handling Hazardous Drugs (HDs) across receipt, storage, compounding, dispensing, and disposal to protect healthcare workers, patients, and the environment.
- The NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 replaced the 2016 list's three groups with two tables: Table 1 (drugs with manufacturer's special handling information and/or NTP/IARC carcinogen classification) and Table 2 (drugs meeting NIOSH criteria without MSHI, including a flag for those that are only a developmental or reproductive hazard).
- HD oral solid dosage forms (tablets/capsules) MUST be counted using dedicated, clearly labeled HD counting trays and spatulas, and must NEVER be counted using automated counting machines (e.g., Kirby Lester) due to hazardous dust contamination.
- Personal Protective Equipment (PPE) for HD handling requires chemotherapy gloves tested to ASTM D6978 standards, lint-free coated gowns, and N95/respirators or PAPRs for aerosol/vapor risks.
- Chemotherapy waste is segregated into Yellow Trace Waste (<3% residual drug, PPE, tubing, empty vials) for high-temperature incineration and Black Bulk RCRA Waste (>3% residual volume, expired full stock, P/U-listed chemicals).
USP <800> Hazardous Drug Identification and Handling Precautions
Core Verification Rule: In technical product verification, a pharmacy technician must identify all hazardous drugs (HDs) listed under NIOSH Groups 1, 2, and 3 and enforce strict USP <800> containment barriers. The verifying technician must confirm that HDs are counted using dedicated, labeled equipment—never automated counting machines—and that proper ASTM D6978 chemotherapy PPE, spill containment, and yellow/black waste segregation standards are maintained.
Healthcare workers handling hazardous drugs face occupational risks including carcinogenicity, teratogenicity, reproductive toxicity, organ toxicity, and genotoxicity. USP General Chapter <800> Hazardous Drugs—Handling in Healthcare Settings establishes mandatory containment standards throughout the medication lifecycle.
1. NIOSH Hazardous Drug Classifications (2024 List — Two Tables, Not Three Groups)
The National Institute for Occupational Safety and Health (NIOSH) maintains the official list that USP <800> and most facility policies point to.
[!WARNING] The structure changed in December 2024. The current publication is the NIOSH List of Hazardous Drugs in Healthcare Settings, 2024 (DHHS (NIOSH) Publication No. 2025-103). It replaced the 2016 list's three groups with two tables. There is no Table 3 anymore, and "antineoplastic" is no longer used as a table descriptor. Older textbooks, courses, and practice banks still teach "Group 1 / Group 2 / Group 3" — if you see that framing, you are looking at the 2016 list.
┌────────────────────────────────────────────────────────────────────────┐
│ NIOSH 2024 LIST -- TABLE STRUCTURE │
├────────────────────────────────────────────────────────────────────────┤
│ TABLE 1 │
│ Drugs that have manufacturer's special handling information (MSHI) │
│ in the package insert, AND/OR meet the NIOSH hazardous drug │
│ definition and are: │
│ • NTP-classified "known to be a human carcinogen", OR │
│ • IARC Group 1 "carcinogenic to humans" or Group 2A "probably │
│ carcinogenic to humans". │
│ NOTE: Not every Table 1 drug is an antineoplastic. │
│ Examples: methotrexate, cyclophosphamide, fluorouracil, cisplatin, │
│ doxorubicin, vincristine, tamoxifen, capecitabine, mercaptopurine, │
│ azathioprine, cyclosporine, ganciclovir. │
│ │
│ TABLE 2 │
│ Drugs that meet one or more NIOSH hazardous drug criteria but │
│ (1) have no MSHI, (2) are not NTP "known human carcinogens", and │
│ (3) are not IARC Group 1 or 2A. A separate column flags the drugs │
│ that are ONLY a developmental and/or reproductive hazard -- the │
│ population that used to sit in the retired Table 3. │
│ Examples: spironolactone, carbamazepine, phenytoin, estradiol, │
│ tacrolimus, finasteride, dutasteride, warfarin, misoprostol, │
│ clonazepam, paroxetine, letrozole, fluconazole. │
└────────────────────────────────────────────────────────────────────────┘
What Moved in the 2024 Update
The 2024 update added 25 drugs (12 of them with MSHI) and removed 7. Several drugs technicians handle routinely also changed tables:
| Drug | 2016 List | 2024 List | Practical Effect |
|---|---|---|---|
| Azathioprine (Imuran) | Group 2 | Table 1 | Now grouped with the highest-containment agents (IARC Group 1 carcinogen). |
| Cyclosporine (Neoral / Gengraf) | Group 2 | Table 1 | Same — IARC Group 1 carcinogen. |
| Ganciclovir (Cytovene) | Group 2 | Table 1 | Has MSHI in the package insert. |
| Finasteride (Proscar / Propecia) | Group 3 | Table 2, flagged developmental/reproductive | Handling precautions unchanged in practice; the table label changed. |
| Warfarin (Coumadin / Jantoven) | Group 3 | Table 2, flagged developmental/reproductive | Still a hazardous drug and still P-listed RCRA waste. |
Comprehensive NIOSH Hazardous Drug Reference Table
| NIOSH 2024 Table | Basis for Listing | Representative Drug Examples | Clinical / Verification Checkpoint |
|---|---|---|---|
| Table 1 | MSHI in the insert, and/or NTP "known human carcinogen" or IARC Group 1 / 2A | • Methotrexate (Trexall)<br>• Cyclophosphamide (Cytoxan)<br>• Fluorouracil (5-FU)<br>• Tamoxifen (Soltamox)<br>• Capecitabine (Xeloda)<br>• Mercaptopurine (Purinethol)<br>• Azathioprine (Imuran)<br>• Cyclosporine (Neoral / Gengraf) | High risk of secondary malignancies and bone marrow suppression. Oral methotrexate for rheumatoid arthritis is dosed WEEKLY (daily dosing causes fatal toxicity). |
| Table 2 | Meets NIOSH criteria; no MSHI; not NTP/IARC classified as above | • Spironolactone (Aldactone)<br>• Carbamazepine (Tegretol)<br>• Estradiol (Estrace / Climara)<br>• Phenytoin (Dilantin)<br>• Tacrolimus (Prograf) | Diuretics, anticonvulsants, hormones, and immunosuppressants meeting organ toxicity, genotoxicity, or carcinogenicity criteria. |
| Table 2, flagged "only developmental and/or reproductive hazard" | Meets NIOSH criteria solely as a developmental/reproductive hazard | • Finasteride (Proscar / Propecia)<br>• Dutasteride (Avodart)<br>• Warfarin (Coumadin)<br>• Misoprostol (Cytotec)<br>• Clonazepam (Klonopin)<br>• Paroxetine (Paxil) | 5-alpha reductase inhibitors (finasteride, dutasteride) can cause genital abnormalities in a developing male fetus, so personnel who are pregnant or trying to conceive must not handle crushed or broken tablets. |
A caution about local policy: USP <800> and many facility policies were written against the 2016 three-group framework and have not all been rewritten. Follow your facility's current Assessment of Risk and hazardous drug list; use the NIOSH 2024 tables to understand why a drug is on it, not to overrule a stricter local standard.
2. Handling, Counting, and Dispensing Precautions
To prevent occupational cross-contamination and unintended exposure, pharmacies must adhere to strict physical handling protocols for hazardous solid dosage forms.
┌────────────────────────────────────────────────────────────────────────┐
│ HD DISPENSING & COUNTING RULES │
├────────────────────────────────────────────────────────────────────────┤
│ 1. DEDICATED COUNTING TRAYS & SPATULAS: │
│ • Must use a dedicated tray and spatula labeled 'HAZARDOUS ONLY'. │
│ • Trays are often color-coded (e.g., bright red or yellow). │
│ │
│ 2. AUTOMATED COUNTING MACHINES STRICTLY PROHIBITED: │
│ • NEVER pour hazardous tablets/capsules into automated counting │
│ machines (e.g., Kirby Lester, Baker Cells, robot dispensers). │
│ • Rationale: Tablet friction generates microscopic hazardous dust │
│ that contaminates subsequent non-hazardous drugs and exposes staff│
│ │
│ 3. DECONTAMINATION & CLEANING PROTOCOL: │
│ • 70% Isopropyl Alcohol (IPA) ALONE DOES NOT DECONTAMINATE! │
│ • Decontamination requires an oxidizing agent (bleach/peroxide), │
│ followed by neutralizing cleaner, then 70% IPA for disinfection. │
└────────────────────────────────────────────────────────────────────────┘
[!CAUTION] The Kirby Lester / Automation Dust Hazard: Counting hazardous tablets (such as methotrexate, spironolactone, or finasteride) in automated counting machines creates invisible aerosolized powder. When a subsequent non-hazardous medication (such as amlodipine) is counted in that same machine, the hazardous chemical residue is transferred directly into the patient's prescription, while technician inhalation of dust creates cumulative systemic toxicity.
3. Personal Protective Equipment (PPE) Standards
USP <800> specifies strict PPE requirements based on the activity being performed (e.g., receiving, counting intact tablets, compounding, or managing spills).
┌────────────────────────────────────────────────────────────────────────┐
│ USP <800> PPE REQUIREMENTS │
├────────────────────────────────────────────────────────────────────────┤
│ • CHEMOTHERAPY GLOVES: │
│ - Must be powder-free and tested to ASTM D6978 standards. │
│ - For compounding/spills: Double gloves (outer over cuff, inner │
│ under cuff); change gloves every 30 MINUTES. │
│ - For counting intact HDs: At least 1 pair ASTM D6978 gloves. │
│ │
│ • CHEMOTHERAPY GOWNS: │
│ - Disposable, lint-free, polyethylene-coated (impermeable). │
│ - Back-closing with long sleeves and elastic/knit cuffs. │
│ - Change every 2 to 3 HOURS (or immediately if contaminated). │
│ │
│ • RESPIRATORY & EYE PROTECTION: │
│ - N95 respirator protects against airborne HD dust particles. │
│ - PAPR (Powered Air-Purifying Respirator) or gas cartridge mask │
│ required for HD vapors, gases, or major spills. │
│ - Goggles / full face shield required when splash risk exists. │
└────────────────────────────────────────────────────────────────────────┘
4. Waste Disposal Segregation: Yellow Trace vs. Black Bulk RCRA
Disposal of hazardous drug residue is governed by both USP <800> and Environmental Protection Agency (EPA) Resource Conservation and Recovery Act (RCRA) regulations.
| Waste Container | Container Type & Color | Waste Content Classification | Representative Disposal Items |
|---|---|---|---|
| YELLOW TRACE WASTE | Yellow Rigid Container (or Yellow Chemo Bag) | Trace Chemotherapy Waste (< 3% residual volume by weight) | • Empty IV bags and tubing<br>• Used chemotherapy gloves and gowns<br>• Empty vials (<3% drug remaining)<br>• Needles, syringes, chemo wipes<br>• Contaminated counting tray paper |
| BLACK BULK RCRA WASTE | Black Rigid Hazardous Container | Bulk Hazardous / RCRA Waste (> 3% residual volume or unempty) | • Partially used / expired HD vials (>3% volume)<br>• Unused chemotherapy doses<br>• P-listed acute hazardous chemical waste (Warfarin, Nicotine, Physostigmine)<br>• Hazardous chemical compounding spill debris |
A pharmacy technician is preparing to count a 90-day supply of Finasteride 5 mg tablets for an outpatient prescription. Which handling and counting procedure must the verifying technician enforce?
Which personal protective equipment (PPE) standard is required under USP <800> for personnel handling and manipulating hazardous drugs?
A hospital technician has just finished compounding an intravenous infusion of Fluorouracil (5-FU). The empty sterile IV compounding bag, used chemotherapy gloves, used alcohol wipes, and empty drug vial are ready for disposal. Into which waste stream container must these items be discarded?
When decontaminating and cleaning a dedicated hazardous drug counting tray and spatula after counting oral methotrexate tablets, which cleaning protocol is required under USP <800>?